Rabbi Richard Louis Price, M.D. is a Yale & Columbia University-trained psychiatry professor at Weill Cornell Medical College/New York-Presbyterian Hospital. Over the past two decades, he has evaluated over 20,000 patients serving as a medical director at Achieve Behavioral Health in Monsey; Rockland TMS & Wellness Center; Hamaspik of Orange and Rockland Counties; Volunteer Counseling Services in New City; ParCare in Brooklyn, Chai Urgent Care Centers, and has a private pediatric and adult psychotherapy and psychopharmacology practice in Monsey, New York.

Dr. Price is triple board certified in Psychiatry, Mind-Body Medicine, and Addiction Medicine and has been awarded numerous patents in the United States, Canada, Europe, and Israel for a novel pharmacotherapy for the treatment of both core and associated symptoms of Autism Spectrum Disorder.

Dr. Price has served on the advisory boards and as a national speaker for several pharmaceutical companies, such as Abbvie, Alkermes, Allergan, Almatica, Axsome, Biogen, Idorsia, Intracellular, Janssen, Jazz, Lundbeck, Neuronetics, Otsuka, Sage, Supernus, Teva, and Vanda and has been recognized as a top Medical Educator by the American Psychiatric Association.

Jesse Jacob Price received his undergraduate business training at New York University Stern School of Business in Manhattan where he was an Honors Research Scholar. Jesse concentrated in finance, statistics, mathematics and computer science and was a member of the Business Analytics Society. He has worked as a data research analyst for world-class thought leaders, such as Finance Professor Dr. Kose John, developing a proposal to be deployed on Ethereum blockchain via smart contact, and creating a Decentralized Finance method to audit the flow of funds and define investment parameters for hedge funds.

He also worked for renowned Statistics Professor Dr. Elynn Chen examining factor models using Principal Component Analysis to reduce dimensionality for forecasting stock return data and valuation. For several years, Jesse processed clinical data leading to international patents on a novel pharmaceutical for Autism Spectrum Disorder and created pitch material for angel investors. Jesse has worked internationally in investment banking and in data analytics where he innovated artificial intelligence and machine learning algorithms for a personalized banking app, dissected transaction data, and contributed an analysis of time series. Jesse is the passionate leader and driving force behind the development of Saadia Pharmaceuticals recognizing the need to leverage novel, disruptive, and safe technologies to meet current healthcare challenges.

Maxwell Zachary Price is a graduate of Columbia College, Columbia University in the City of New York concentrating in Computational Neuroscience. He is currently a research scientist at Hackensack University Medical Center where he has received his medical school and Masters of Public Health in Biostatistics training. Maxwell has published numerous peer-reviewed articles in prestigious journals, such as Lancet, British Medical Journal, CNS Drugs, The Journal of Clinical Psychiatry, and Nature covering a range of topics including Attention Deficit Hyperactivity Disorder, Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Alzheimer’s Disease, Metabolic Syndrome, Addiction, and Borderline Personality.

His impactful research has been covered by international medical news outlets, such as Medscape. He has patented a novel treatment for carcinogenic harmful blooms and has researched a novel treatment approach to Multiple Sclerosis using an angiogenesis inhibitor. Maxwell has developed a concept for the launch of an artificial intelligence psychiatry platform to assist practitioners and patients with more accurate diagnoses and treatment algorithms and has published a patent enabling the first oral medication for Treatment-Resistant Depression in over 20 years. Maxwell has presented his research at Psych Congress and Neuroscience Education Institute, where his poster won first place in 2023.

Elie Pariente-Cohen is a finance professional whose career spans notable achievements in corporate development, investment banking, and strategic investments, particularly within the media and FinTech sectors. He graduated with honors from New York University’s Stern School of Business with a focus in Finance and Global Business. Most recently, at BuzzFeed Inc., Elie played a crucial role in leading the sale of part of Complex Networks to NTWRK for approximately $109M. He also led the development of a new liquidity forecast model to improve BuzzFeed’s cash management and helped format, coordinate, and create board materials. At Financial Technology Partners, Elie assisted in forecasting client financials to prepare them for M&A or financing transactions. He also coordinated with deal teams to prepare materials regarding valuation, financials, and business management for investors.


At both BuzzFeed and Financial Technology Partners, Elie provided insight concerning company strategy for various brands and businesses in Media and FinTech. While pursuing his studies at NYU Stern School of Business, he founded Hummingbird Capital Fund and focused on cryptocurrency investments that yielded an impressive ~1,100% ROI for investors. At AIG, his analytical skills shone through in his work analyzing the thesis behind multiple models, producing insightful data that informed strategic decisions throughout the AIG organization. He has a blend of strategic insight, analytical prowess, and innovative thinking combined with a passion to support and help pave the future.